(Q39785030)

14 September 2017

title

Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor (English)

1 reference

14 September 2017

Peter J Buontempo

1

1 reference

14 September 2017

Lisa Wojcik

2

1 reference

14 September 2017

Catherine A Buontempo

3

1 reference

14 September 2017

Robert A Ogert

4

1 reference

14 September 2017

Julie M Strizki

5

1 reference

14 September 2017

John A Howe

6

1 reference

14 September 2017

Robert Ralston

7

1 reference

14 September 2017

language of work or name

English

0 references

publication date

20 October 2009

1 reference

14 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

14 September 2017

volume

395

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

268-279

1 reference

Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

G protein-coupled receptor allosterism and complexing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Analysis of allosterism in functional assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Allosteric modulators: the new generation of receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Principles: receptor theory in pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Determining the potency and molecular mechanism of action of insurmountable antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Estimating the stoichiometry of human immunodeficiency virus entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Allosteric Modulation of G Protein–Coupled Receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Chemokine receptor CCR5: insights into structure, function, and regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Targeting HIV attachment and entry for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.029

10.1016/J.VIROL.2009.09.029

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference